메뉴 건너뛰기
New England Journal of Medicine
Volumn 366, Issue 3, 2012, Pages 271-273
RAF around the edges - The paradox of BRAF inhibitors
Author keywords

[No Author keywords available]
Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MUTANT PROTEIN; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; VEMURAFENIB;
EID: 84856190949     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1111636     Document Type: Editorial
Times cited : (43)
References (7)
  • 1
    • 79952003197 scopus 로고    scopus 로고
    • RAF inhibition and induction of cutaneous squamous cell carcinoma
    • Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011;23:177-82.
    • (2011) Curr Opin Oncol , vol.23 , pp. 177-182
    • Robert, C.1    Arnault, J.P.2    Mateus, C.3
  • 2
    • 84862908097 scopus 로고    scopus 로고
    • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
    • Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15.
    • (2012) N Engl J Med , vol.366 , pp. 207-215
    • Su, F.1    Viros, A.2    Milagre, C.3
  • 3
    • 79960027865 scopus 로고    scopus 로고
    • BRAF targeted therapy changes the treatment paradigm in melanoma
    • Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011;8: 426-33.
    • (2011) Nat Rev Clin Oncol , vol.8 , pp. 426-433
    • Ribas, A.1    Flaherty, K.T.2
  • 4
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3    Shokat, K.M.4    Rosen, N.5
  • 5
    • 74849109743 scopus 로고    scopus 로고
    • Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
    • Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21.
    • (2010) Cell , vol.140 , pp. 209-221
    • Heidorn, S.J.1    Milagre, C.2    Whittaker, S.3
  • 6
    • 78650008177 scopus 로고    scopus 로고
    • Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
    • Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95.
    • (2010) Cancer Cell , vol.18 , pp. 683-695
    • Villanueva, J.1    Vultur, A.2    Lee, J.T.3
  • 7
    • 78650303507 scopus 로고    scopus 로고
    • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    • Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
    • (2010) Nature , vol.468 , pp. 973-977
    • Nazarian, R.1    Shi, H.2    Wang, Q.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.